Drugs precisely delivered by suprachoroidal injection with access to the choroid and the retina where the diseases present.
Henry F. Edelhauser
Eye diseases such as uveitis, retinal vein occlusion and diabetic macular edema present in the choroid and retina. Through the ingenious efforts of our research and development team, we have developed a unique and elegant way to access to the choroid and retina through the suprachoroidal space to treat these diseases.
Rapid vision gains 
Sustained better vision improvement Consistent patient response Improved benefits to risk ratio
CLS-TA administered by suprachoroidal injection is currently under investigation in clinical trials.
Not available for clinical use. Not approved by the FDA or other regulatory bodies.
